Cancer Treatment Reviews
Volume 29 , Pages 3-9 , May 2003

The proteasome: structure, function, and role in the cell

  • Julian Adams

      Affiliations

    • Corresponding Author InformationCorrespondence to: Julian Adams PhD, Millennium Pharmaceuticals, Inc., 35 Landsdowne Street, Cambridge, MA 02139, USA. Tel.: 1-617-551-3674; Fax: 1-617-761-6864

References 

  1. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 2001;8(8):739–758
  2. Kumatori A, Tanaka K, Inamura N, et al.  Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA. 1990;87(18):7071–7075
  3. LeBlanc R, Catley LP, Hideshima T, et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62(17):4996–5000
  4. Hideshima T, Richardson P, Chauhan D, et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–3076
  5. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 2000;6(9):3719–3728
  6. Shah SA, Potter MW, McDade TP, et al.  26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 2001;82(1):110–122
  7. Sunwoo JB, Chen Z, Dong G, et al.  Novel proteasome inhibitor PS-341 inhibits activation of Nuclear Factor-KappaB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001;7(5):1419–1428
  8. Adams J, Palombella VJ, Sausville EA, et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615–2622
  9. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. P53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 2001;8(3):210–218
  10. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res. 1998;58(19):4342–4348
  11. Masdehors P, Omura S, Merle-Beral H, et al.  Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 1999;105(3):752–757
  12. Delic J, Masdehors P, Omura S, et al.  The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br. J. Cancer. 1998;77(7):1103–1107
  13. Wilkinson KD. Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment. J. Nutr. 1999;129(11):1933–1936
  14. Pickart CM. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001;70:503–533
  15. Zwickl P, Voges D, Baumeister W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 1999;354(1389):1501–1511
  16. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S Proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J. Mol. Biol. 2001;311(3):543–548
  17. Nussbaum AK, Dick TP, Keilholz W, et al.  Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of Enolase 1. Proc. Natl. Acad. Sci. USA. 1998;95(21):12504–12509
  18. Adams J, Behnke M, Chen S, et al.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 1998;8(4):333–338
  19. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin rbeta-lactone. J. Biol. Chem. 1996;271(13):7273–7276
  20. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli Homolog HslV by a new class of inhibitors. Proc. Natl. Acad. Sci. USA. 1997;94(13):6629–6634
  21. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl. Acad. Sci. USA. 1999;96(18):10403–10408
  22. Meng L, Kwok BH, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 1999;59(12):2798–2801
  23. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of Wt P53, P21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia. 2000;14(7):1276–1283
  24. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM. Inhibition of Nuclear Factor KappaB activation attenuates apoptosis resistance in lymphoid cells. Blood. 1998;91(12):4624–4631
  25. Wu Y, Luo H, Kanaan N, Wu J. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J. Cell Biochem. 2000;76(4):596–604
  26. Chiarle R, Budel LM, Skolnik J, et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor P27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95(2):619–626
  27. Lloyd RV, Erickson LA, Jin L, et al.  P27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol. 1999;154(2):313–323
  28. Chen C, Edelstein LC, Gelinas C. The Rel/NF-KappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. 2000;20(8):2687–2695
  29. Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-KappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell Biol. 1999;19(9):5923–5929
  30. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and C-IAP1 and C-IAP2 to suppress caspase-8 activation. Science. 1998;281(5383):1680–1683
  31. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet. 2000;355(9200):248–250
  32. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14(3):399–402
  33. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. 1999;13(4):382–387
  34. Patel NM, Nozaki S, Shortle NH, et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκB α super-repressor and parthenolide. Oncogene. 2000;19(36):4159–4169
  35. Um JH, Kang CD, Lee BG, Kim DW, Chung BS, Kim SH. Increased and correlated Nuclear Factor-KappaB and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene. 2001;20(42):6048–6056
  36. Cusack JC, Liu R, Houston M, et al.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic Nuclear FactorKappaB inhibition. Cancer Res. 2001;61(9):3535–3540
  37. Russo SM, Tepper JE, Baldwin AS, et al.  Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 2001;50(1):183–193
  38. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 2001;100(1):11–17
  39. Kurland JF, Meyn RE. Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. Int. J. Cancer. 2001;96(6):327–333
  40. Fan XM, Wong BC, Wang WP, et al.  Inhibition of proteasome function induced apoptosis in gastric cancer. Int. J. Cancer. 2001;93(4):481–488
  41. LeBlanc R, Catley L, Hideshima T, Pien CS, Elliott PJ, Anderson KC. Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. Blood. 2001;98(11):774a
  42. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of P21WAF1/Cip1 in human immature leukemic cells. Eur. J. Haematol. 2000;65(4):221–236
  43. Steiner P, Neumeier H, Lightcap ES, et al.  Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood. 2001;98(11):310a
  44. Neumeier H, Hoar, K, Pink M, et al. Hypoxia increases potency of the proteasome inhibitor VELCADE (TM) (bortezomib) for injection: potential for a hypoxic cell cytotoxin in solid tumors. Presented at the EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics; November 19–22, 2002; Frankfurt, Germany
  45. Soligo D, Servida F, Delia D, et al.  The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol. 2001;113(1):126–135
  46. Masdehors P, Merle-Beral H, Magdelenat H, Delic J. Ubiquitin–proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk. Lymphoma. 2000;38(5-6):499–504
  47. Kudo Y, Takata T, Ogawa I, et al.  P27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 2000;6(3):916–923

PII: S0305-7372(03)00081-1

doi: 10.1016/S0305-7372(03)00081-1

Cancer Treatment Reviews
Volume 29 , Pages 3-9 , May 2003

Article Tools

* Image Usage & Resolution